**DEPRESSION CORRELATES WITH QUALITY OF LIFE IN PEOPLE WITH EPILEPSY INDEPENDENT OF THE MEASURES USED**

Proposed paper for Epilepsy & Behaviour

Word Count: 2639, References 25, Tables 3, Figures 2

**Niruj Agrawal1,2,3\*, Jacob S Bird1, Tim J von Oertzen3,5, Hannah Cock2,3, Alex J Mitchell4, Marco Mula2,3**

1. Department of Neuropsychiatry, South West London & St George’s MH NHS Trust, St George's Hospital, London, UK
2. Epilepsy Group, Atkinson Morley Regional Neuroscience Centre, St George’s Hospital, London, UK
3. Institute of Medical and Biomedical Sciences, St George’s University of London, UK
4. Leicestershire Partnership Trust, Leicester and Department of Cancer Studies and Molecular Medicine, University of Leicester, UK
5. Department of Neurology, Wagner-Jauregg Neuroscience Centre, Linz, Austria

\* Correspondence:

Niruj Agrawal

Consultant Neuropsychiatrist

Department of Neuropsychiatry

Clare House, St George’s Hospital

Blackshaw Road, London SW17 0QT

Email: [Niruj.Agrawal@swlstg-tr.nhs.uk](mailto:Niruj.Agrawal@swlstg-tr.nhs.uk)

Tel. +44 208 725 3786

Fax. +44 208 725 2929

**ABSTRACT**

Purpose: A number of studies have suggested that depressed mood is one of the most important predictors of quality of life (QoL) in patients with epilepsy. However, QoL measure used in previous studies was limited to the Quality Of Life in Epilepsy (QOLIE) scales. It could be questioned whether correlation of QOLIE with measures of depression is influenced by the properties of the instruments used rather than being a valid effect. By using visual analogue scales, the current study aims to clarify whether depression and QoL are truly correlated in patients with epilepsy.

Methods: Data from a sample of 261 outpatients with epilepsy attending the Epilepsy Clinics of the Atkinson Morley Outpatient Department, St George’s Hospital in London, have been analysed. Patients were screened using the European Quality of Life scale (EQ-5D-3L) which includes an overall visual analogue score (EQ-VAS), the Emotional Thermometer (ET7), Beck Depression Inventory-II (BDI-II), the Hospital Anxiety and Depression Scale (HADS), and the Major Depression Inventory (MDI).

Results: Depression was found to significantly correlate with EQ-VAS score with *r* coefficient ranging from 0.42 to 0.51 and *r2*coefficients ranging between 0.18 and 0.26. In addition, we identified patients who were depressed according to DSM-IV criteria (MD) and those with atypical forms of depression (AD). EQ-5D-3L scores in these subjects as compared to those without depression (ND) showed a different impact of AD and MD on QoL.

Conclusions: The relationship between depression and quality of life in people with epilepsy has been demonstrated to be a robust and valid effect, not a result of potential bias of the specific measures used. However, the strength of the association is influenced by the individual instrument. Atypical or subsyndromic forms of depression are as relevant as DSM-based depression in terms of impact on QoL.

**KEY WORDS:** Epilepsy, depression, quality of life, screening and emotional thermometer.

1. **Introduction**

Depression is the most frequently reported psychiatric comorbidity among patients with epilepsy. The life-time prevalence rates range between 24% in community-based studies (1), to 50% in tertiary referral centres or surgery programs (2). Reasons for such a close link are both biological and psychosocial (3). In fact, on one hand, epilepsy is a chronic disorder which brings about social discriminations, burden and limitations (4) on the other hand, neuroimaging and neurobiological studies are emphasizing the biological contribution to this association based on neuroanatomical and neurochemical principles (5). This is further supported by epidemiological studies suggesting a bidirectional relationship between the two disorders, namely that depression does not always follow the onset of the epilepsy but it may also precede the onset of a seizure disorder (6, 7), suggesting an underlying common neurobiological background (8).

A number of studies pointed out that depression is the most important predictor of quality of life (QoL), perhaps even more than seizures themselves (9-12).In addition, depression has been shown to be associated with poor response of epilepsy to antiepileptic drugs (AEDs) (13), as well as poor outcome after epilepsy surgery (14). So far, the effect of depression on QoL in patients with epilepsy has been demonstrated using the same QoL scale, namely Quality of Life in Epilepsy (QOLIE, either 89 or 31). Moreover, most of the studies have used the Beck Depression inventory (BDI) as a measure for depression and, only recently, the Hospital Anxiety and Depression scale (HADS). While the evidence to date shows a strong correlation between depression scores and QoL, it remains unclear whether this is a true effect or a function of potential biases associated with the specific scales used, namely QOLIE and Beck Depression inventory (BDI) or Hospital Anxiety and Depression scale (HADS).

This study aims to examine the association between depression and QoL in patients with epilepsy using a different independently validated QoL instrument consisting of a visual analogue scale and four different validated measures of depression including a visual analogue scale based instrument. The potentially different impact of different forms of depression, satisfying DSM-IV criteria and atypical forms or subsyndromic forms, on QoL is also examined.

**2. Methods**

This study includes data collected as part of a service improvement project at the Outpatient Epilepsy Clinics, Atkinson Morley Neurosciences Centre, St George’s Hospital in London. Over a ten-month period, as a routine, all patients with an established diagnosis of epilepsy according to ILAE criteria, were given a number of questionnaires including those for mood and QoL. Patients with severe learning disabilities, gross cognitive abnormalities or poor English language skills were excluded from this study.

Participation was voluntary and anonymously collected data was subsequently analysed for the purpose of this study. Local Research Ethic Committee deemed the project as a service development project not requiring formal research ethics approval for anonymised data previously collected.

All subjects completed the Beck Depression Inventory (BDI-II) (15), the Hospital Anxiety and Depression Scale (HADS) (16), the Neurological Disorders Depression Inventory for Epilepsy (NDDI-E) (17) and the Emotional Thermometer (ET-7) (18). A Diagnostic and Statistical Manual-IV (DSM-IV) diagnosis of depression was made using the Major Depression Inventory (MDI) (19), which was administered to all patients. Quality of life was measured using the EQ-5D-3L (20) which includes an overall visual analogue scale (EQ-VAS).

Both BDI-II and HADS are well known screening instruments for depression and both have been validated in the epilepsy setting (21, 22). The NDDI-E is a well-known clinical instrument, developed for the rapid and objective detection of a major depressive episode in patients with epilepsy. It has been found to be a very practical and user-friendly screening instrument in an outpatient setting. The ET7 is a screening tool made up of seven visual analogue scales also validated in patients with epilepsy with a sensitivity of 85.1% and specificity of 78.8%, PPV of 0.463 and NPV of 0.961. The MDI is a self-administered WHO scale which is able to generate an ICD-10 or DSM-IV diagnosis of clinical depression in addition to an estimate of symptom severity.

The EQ-5D-3L consists of two measures namely the European Quality of life Visual Analogue Scale (EQ-VAS) and the European Quality of life 5 Dimension scale (EQ-5D). EQ-VAS is a visual-analogue scale, similar in appearance to a thermometer, for recording an individual’s rating for their current health-related quality of life state from ‘best imaginable health state’ at the top with a rating of 100, to ‘worst imaginable health state’ at the bottom with a rating of 0. Patients mark the point on the scale corresponding to their overall health state. The EQ-5D consists of five dimensions; mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each of these dimensions can take one of three responses representing three levels of severity; no problems, some or moderate problems, or extreme problems.

Frequencies of categorical demographic and clinical variables were analysed using the χ2 analysis or Fisher’s exact test. Continuous demographic and clinical variables, BDI, HADS, AEP and ET scores were compared using the Student’s t-test for independent samples. Correlations were tested using a bivariate two-tailed parametric correlation procedure (Pearson’s coefficient) and simple linear regression procedures. The alpha error was set at 0.05.

Patients with depression have been then categorised in two different groups. Those with a DSM-IV diagnosis according to the MDI and those who did not satisfied DSM criteria but presented a positive screening at the NDDIE, representing atypical forms of depression. One-way analysis of variance (ANOVA) with post-hoc pairwise Tukey’s comparisons was used to compare EQ-5D-3L scores in these patients as compared to subjects without depression (negative MDI and NDDIE). In this case, the probability level was set to 0.016 (0.05/3) to reduce the Type-I error associated with multiple comparisons. All statistical analyses were 2-tailed and conducted using the Statistical Package for Social Sciences (Version 21 for Windows, SPSS Inc. Chicago, IL).

1. **RESULTS**

Our sample includes 261 patients. Clinical and demographic characteristics are shown in **Table 1**. EQ-VAS scores inversely correlated with all measures of depression with coefficients ranging between r = -0.509 (p<0.001) for BDI-II to r = -0.420 (p<0.001) for NDDIE (**Table 2**). Adjusted linear regression scores and scatter plots are shown in **Figure 1**.

Utilising the MDI 41 patients received a DSM-IV diagnosis of Major Depression (MD) while 90 had a positive screening with the NDDIE. We, therefore, identified 49 patients who scored positive according to the NDDIE screening but did not fulfil DSM criteria for depression representing a group of patients with either atypical forms of depression (AD) or subsyndromic depressive episode (SSDE). EQ-5D-3L scores in these subjects as compared to those without depression (ND) showed a different impact of AD and MD on QoL (**Table 3**). AD is as relevant as MD in terms of QoL in general, as measured with the EQ VAS, and limitations in daily activities (e.g. work, study, housework, family or leisure activities) as measured with the EQ5D Usual activities subscale.

1. **Discussion**

Our results confirm that QoL correlates with depression in patients with epilepsy irrespective of the instruments used to measure either QoL or depression including use of visual analogue measures. This suggests that the correlation of depression with QoL is a valid effect, and not a function of potential biases of the individual scales used. In fact, the EQ-VAS is a visual-analogue scale and, by definition, neutral in terms of specific items that might have a strong correlation with depression as it happens for the QOLIE. In addition, correlation coefficients are quite similar among the four different clinical instruments for depression used in our study, further confirming the true correlation with QoL.

Our results should be discussed in the light of previous studies on QoL in epilepsy. The paper by Boylan (9) using the BDI and QOLIE31 reported a r² = 0.51, with values ranging from r² = 0.18 for seizure worry to 0.44 for emotional wellbeing. An earlier paper by Cramer et al. (10) using the Center for Epidemiologic Studies Depression Scale (CES-D) and QOLIE89, reported a correlation score r = - 0.723. A subsequent paper from the same group using the HADS-D and the QOLIE-10 found a correlation coefficient r² = 0.51(23). Our study showed coefficients r2 = 0.259 for the BDI-II and r² = 0.26 for the HADS-D, suggesting that depression indeed correlates with QoL and but the strength of the association could have been influenced by the adopted clinical instrument. In fact, the QOLIE questionnaires have three specific subscales covering Emotional well-being, Energy and fatigue and Cognitive functioning and all these domains strongly correlate also with depression(10). In the first paper by Cramer et al.(10) CESD scores showed correlation scores up to -0.776 for the Emotional well-being as compared to other domains such as Seizure worry (r=-0.386) or Physical function (r=-0.320). It is, thus, evident that the way the individual instrument is structured may influence the strength of the association with depression.

The aim of this study is not to criticize the QOLIE series (QOLIE10, 31 or 89) or their reliability. On the contrary, our aim was to finally demonstrate that depression truly correlates with QoL in patients with epilepsy. Having said that, QoL is a multidimensional construct and as such, good clinical instruments should include generic domains (i.e. those designed to assess health status among patients with different health states, conditions, and diseases) and domains specific to single diseases. It is now established that emotional well-being is an important part of QoL in patients with epilepsy and it is, therefore, evident that questionnaires covering all these aspects, such as the QOLIE series, should be preferred when planning a QoL study in epilepsy.

Obviously other differences may be responsible for the different correlations observed in our study. In the study by Boylan et al.9, the prevalence of depression was as high as 54% while, in our study, it was 18%. An interaction between the two factors may therefore be more difficult to tease out, or less profound in our study. Most of the studies focused on selected samples of patients with drug-refractory epilepsies while our study investigated an unselected sample of consecutive patients referred to our Outpatient Clinics.

The different pattern of QoL impairment among people with typical depression fulfilling DSM criteria (MD) and atypical depression (AD) or subsyndromic depressive episode (SSDE) is another interesting finding of our study. MD showed to have a significant impact on each of the five domains of EQ-5D. Obviously, it is difficult to say whether all patients who had a positive NDDIE screening were depressed considering that it has a positive predictive value of 53%. However, our data suggest that probably these patients have either an atypical form of depression which do not get diagnosed as major depression as per DSM criteria or subsyndromic depressive episode as they presented with lower scores for QoL as compared to patients without depression and in a similar fashion as compared with patients with a DSM based diagnosis of depression. It is now evident that mood disorders in epilepsy present a number of atypical features that are not efficiently captured by standardized clinical instruments shaped on DSM criteria. Reasons for such atypical features are still matter of debate (5, 24). On one hand, they may be secondary to the antiepileptic drug (AED) treatment and peri-ictal symptoms. On the other hand, increasing evidence is pointing out that some patients may present with a peculiar mood syndrome largely atypical from those described by international diagnostic systems (i.e. ICD and DSM), namely the interictal dysphoric disorder (IDD) (25). It is not possible to be certain whether the patients had IDD in our sample.

Finally, our findings should be considered bearing in mind the following limitations. First, seizure frequency was not reported as well as the proportion of seizure free patients. However, our aim was not to dissect out the relative contribution of depression to QoL as compared to depression but verify the correlation between QoL measure with a neutral clinical instruments, namely a visual analogue scale, against different measures of depression. Second, our results may not be representative of the general population of patients with epilepsy as they come from a tertiary referral centre where more severe and drug-refractory cases are present. However, the majority of other studies in this area have been done in selected samples.

In conclusion, our study helps substantiate the finding of correlation of depression with QoL in patients with epilepsy. However, clinical utility of this finding must be explored. All the evidence so far has looked at this correlation in cross-sectional studies. It remains unclear whether identification and treatment of depression in patients with epilepsy would lead to an appreciable, real world improvement in their quality of life. It seems logical to assume so, however, there may be as yet unidentified moderators involved in the process, and isolating the depressive effects of anti-epileptic drugs would need to be controlled for. Prospective cohort studies are now required to clarify whether this would indeed be the case.

**DISCLOSURES**

Alex J Mitchell holds the copyright on the revised Emotional Thermometers tool but has made it freely available (royalty-free) for non-commercial and clinical use. The remaining authors have no conflicts of interest. We confirm that we have read the journal’s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

**References**

1. Tellez-Zenteno JF, Patten SB, Jette N, Williams J, Wiebe S. Psychiatric comorbidity in epilepsy: a population-based analysis. Epilepsia. 2007 Dec;48(12):2336-44.

2. Kanner AM. Depression in epilepsy: a frequently neglected multifaceted disorder. Epilepsy Behav. 2003 Dec;4 Suppl 4:11-9.

3. Lin JJ, Mula M, Hermann BP. Uncovering the neurobehavioural comorbidities of epilepsy over the lifespan. Lancet. [Research Support, N.I.H., Extramural

Review]. 2012 Sep 29;380(9848):1180-92.

4. de Boer HM, Mula M, Sander JW. The global burden and stigma of epilepsy. Epilepsy Behav. 2008 May;12(4):540-6.

5. Mula M, Schmitz B. Depression in epilepsy: mechanisms and therapeutic approach. Ther Adv Neurol Disord. 2009 Sep;2(5):337-44.

6. Hesdorffer DC, Hauser WA, Olafsson E, Ludvigsson P, Kjartansson O. Depression and suicide attempt as risk factors for incident unprovoked seizures. Ann Neurol. 2006 Jan;59(1):35-41.

7. Hesdorffer DC, Ishihara L, Mynepalli L, Webb DJ, Weil J, Hauser WA. Epilepsy, suicidality, and psychiatric disorders: a bidirectional association. Ann Neurol. [Research Support, Non-U.S. Gov't]. 2012 Aug;72(2):184-91.

8. Mula M. Epilepsy: Bidirectional link between epilepsy and psychiatric disorders. Nat Rev Neurol. 2012;8(5):252-3.

9. Boylan LS, Flint LA, Labovitz DL, Jackson SC, Starner K, Devinsky O. Depression but not seizure frequency predicts quality of life in treatment-resistant epilepsy. Neurology. 2004 Jan 27;62(2):258-61.

10. Cramer JA, Blum D, Reed M, Fanning K. The influence of comorbid depression on quality of life for people with epilepsy. Epilepsy Behav. 2003 Oct;4(5):515-21.

11. Eddy CM, Rizzo R, Gulisano M, Cali P, Robertson MM, Cavanna AE. Quality of life in young people with treatment-responsive epilepsy: A controlled study. Epilepsy Behav. 2010 Dec;19(4):623-6.

12. Gilliam F. Optimizing health outcomes in active epilepsy. Neurology. 2002 Apr 23;58(8 Suppl 5):S9-20.

13. Hitiris N, Mohanraj R, Norrie J, Brodie MJ. Mortality in epilepsy. Epilepsy Behav. 2007 May;10(3):363-76.

14. Kanner AM. Depression in epilepsy: a complex relation with unexpected consequences. Curr Opin Neurol. 2008 Apr;21(2):190-4.

15. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. . Arch Gen Psychiatry 1961;4:561-71.

16. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983 Jun;67(6):361-70.

17. Gilliam FG, Barry JJ, Hermann BP, Meador KJ, Vahle V, Kanner AM. Rapid detection of major depression in epilepsy: a multicentre study. Lancet Neurol. 2006 May;5(5):399-405.

18. Rampling J, Mitchell AJ, Von Oertzen T, Docker J, Jackson J, Cock H, et al. Screening for depression in epilepsy clinics. A comparison of conventional and visual-analog methods. Epilepsia. 2012 Oct;53(10):1713-21.

19. Bech P, Rasmussen NA, Olsen LR, Noerholm V, Abildgaard W. The sensitivity and specificity of the Major Depression Inventory, using the Present State Examination as the index of diagnostic validity. J Affect Disord. [Clinical Trial

Randomized Controlled Trial]. 2001 Oct;66(2-3):159-64.

20. Group TE. EuroQol a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199-208.

21. Jones JE, Hermann BP, Woodard JL, Barry JJ, Gilliam F, Kanner AM, et al. Screening for major depression in epilepsy with common self-report depression inventories. Epilepsia. 2005 May;46(5):731-5.

22. Al-Asmi A, Dorvlo AS, Burke DT, Al-Adawi S, Al-Zaabi A, Al-Zadjali HA, et al. The detection of mood and anxiety in people with epilepsy using two-phase designs: experiences from a tertiary care centre in Oman. Epilepsy Res. 2012 Feb;98(2-3):174-81.

23. Cramer JA, Brandenburg N, Xu X. Differentiating anxiety and depression symptoms in patients with partial epilepsy. Epilepsy Behav. 2005 Jun;6(4):563-9.

24. Kanner AM. Depression and epilepsy: a review of multiple facets of their close relation. Neurol Clin. 2009 Nov;27(4):865-80.

25. Mula M. The interictal dysphoric disorder of epilepsy: a still open debate. Curr Neurol Neurosci Rep. 2013 Jun;13(6):355.

**Table 1. Clinical and demographic characteristics (Total N = 261).**

|  |  |
| --- | --- |
| **Mean Age**, (years range) | 39.3 (16-89) |
| **Gender** %  Female  Male | 54.0%  46.0% |
| **Ethnicity** %  White  Black  Asian  Mixed Race  Unknown | 80.1%  8.1%  6.1%  4.2%  1.5% |
| **Epilepsy type** %  Generalised  Focal  Unknown | 37.2%  57.8%  5.0% |
| **DSM IV diagnosis of depression (MDI)** | 17.6% |
| **BDI mean score (SD)** | 13 (11) |
| **HADS-D, mean score (SD)**  **HADS-A, mean score (SD)** | 4.9 (4.4)  7.2 (4.9) |
| **ET-D, mean score (SD)** | 3.0 (2.9) |
| **NDDIE, mean score (SD)** | 12.3 (4.3) |
| **NDDIE positive screening for depression** | 34.5% |
| **EQ-VAS mean score (SD)** | 66.8 (21.4) |

**Table 2 . Correlations of EQ-VAS with depression screening scales.**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Pearson correlation | EQ-VAS | BDI-II | HADS-D | ET-D | NDDI-E |
| EQ-VAS | 1 | -0.509\*\* | -0.505\*\* | -0.443\*\* | -0.420\*\* |
| BDI-II | -0.509\*\* | 1 | 0.771\*\* | 0.741\*\* | 0.773\*\* |
| HADS-D | -0.505\*\* | 0.771\*\* | 1 | 0.689\*\* | 0.661\*\* |
| ET-D | -0.443\*\* | 0.741\*\* | 0.689\*\* | 1 | 0.695\*\* |
| NDDI-E | -0.420\*\* | 0.773\*\* | 0.661\*\* | 0.695\*\* | 1 |

\*\* p<0.001

**Table 3. Quality of life scores (EQ-5D-3L) in patients with a DSM-based diagnosis of depression (MD), atypical depression (AD) and without depression (ND).**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **MD**  **N=41** | **AD**  **N=49** | **ND**  **N=166** | **ANOVA p value** | **Tukey p value** |
| **EQ VAS (SD)** | 52.1 (24.8) | 60.5 (18.2) | 72.7 (19.2) | F=20.609 p<0.001 | MD>ND p<0.001  AD>ND p=0.001 |
| **EQ Mobility (SD)** | 1.4 (0.5) | 1.2 (0.4) | 1.2 (0.4) | F=5.385 p=0.005 | MD>ND p=0.004 |
| **EQ Self-care (SD)** | 1.2 (0.4) | 1.1 (0.3) | 1.0 (0.2) | F=5.177 p=0.006 | MD>ND p=0.007 |
| **EQ Activities (SD)** | 1.7 (0.7) | 1.6 (0.6) | 1.2 (0.5) | F=16.853 p<0.001 | MD>ND p<0.001  AD>ND p=0.001 |
| **EQ Pain (SD)** | 1.8 (0.7) | 1.5 (0.5) | 1.3 (0.5) | F=13.825 p<0.001 | MD>AD p=0.015  MD>ND p<0.001 |
| **EQ Anx/Dep (SD)** | 2.1 (0.5) | 1.7 (0.5) | 1.3 (0.5) | F=43.797 p<0.001 | MD>AD>ND p=0.001 |

**Figure 1. Scatter plot for EQ-VAS and BDI-II (a), HADS-D (b), ET-Dep (c) and NDDI-E (d).**



 

Figure 2. QoL impairment by EQ-5D domains in patients with and without a DSM diagnosis of depression.

